RT by @ylecun: There are two separate questions regarding Dario Amodei’s post about AI and biology…

TL;DR - A critical take on claims that frontier AI could cure major diseases, arguing that scientific value does not justify concentrated corporate control. AI may accelerate biological research, but physical experiments, clinical trials, and governance remain major constraints.

• AI can speed literature review, target discovery, molecular design, experimental planning, and analysis.
• Wet-lab work, toxicity studies, human trials, manufacturing, and long-term validation cannot scale at software speed.
• Delaying frontier AI could also delay medical advances, creating real human costs.
• Even successful cures would not resolve concerns about access, accountability, competition, data rights, or control of AI.